AMLX (Amylyx Corp) Market Value to Book Value Ratio

Official company branding of Amylyx Pharmaceuticals Inc (AMLX)

This chart of current Amylyx Pharmaceuticals (AMLX) quotes on GURU.Markets serves as an indicator for a business where management is revising its development vector following the withdrawal of its primary product from the market, while the efficiency of neurodrug distribution through a warehouse network ensures returns at the level of 13.30. Supply stability is maintained by a strict temperature-controlled transport regime, which increases logistics costs but guarantees the quality of therapy.

AMLX - amylyx.com Market-to-Book Ratio over the range 07/04/2022 - 10/28/2026
Original product of Amylyx

The scale of investments by Amylyx Pharmaceuticals (AMLX) into robotic molecular screening determines the price action of the market-to-book ratio chart. This indicator compares the exchange valuation with actual net assets, measuring the gap between market expectations and factual capitalization, which allows an investor to identify either an undervalued business or a critical risk of capital impairment over the long term.

Direct competitors

Market Cap to Net Assets Ratio Biogen Inc.|NBIX (neurocrine.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|Biohaven Corp (BHVN) - Market-to-Book Ratio|TRVI (Trevi Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PRAX|Market Value to Book Value Ratio AVXL (Anavex Life Sciences Corp.)|Market Cap to Net Assets Ratio CeriBell Inc CBLL|PRTA: Market Cap to Net Assets Ratio|Alector Inc. - Market-to-Book Ratio|ANNX - Market Value to Book Value Ratio|Omeros Corporation (OMER) - Market Value to Book Value Ratio|Market Cap to Net Assets Ratio NGNE|Market-to-Book Ratio AC Immune S.A.|Market Cap to Net Assets Ratio Voyager Pharma (VYGR)|Capitalization to Book Value Ratio Neumora Corp (NMRA)|Scilex Holding Company (SCLX) - Market Cap to Net Assets Ratio|Market Value to Book Value TVGN (tevogen.com)|Alpha Cognition Inc. (ACOG) - Market Value to Book Value Ratio|Market Capitalization to Net Assets cogrx.com CGTX|Market Capitalization to Book Value Ratio Inhibikase (IKT)|SAVA - Market Value to Book Value|ASRT: Market Capitalization to Book Value Ratio|COYA (Coya Therapeutics) - Market Capitalization to Book Value Ratio|VTGN - Market Value to Book Value Ratio|Market Value to Book Value OVID|Market Value to Book Value Ratio ABOS (Acumen Pharma)|Market Cap to Net Assets Ratio CervoMed Corporation (CRVO)|Market Capitalization to Book Value Ratio ATHE (Alterity Therapeutics Limited)|Market Capitalization to Book Value Ratio Clene Inc CLNN|PEPG: Market Capitalization to Book Value Ratio|JUNS - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio RLMD|Market-to-Book Ratio Annovis Bio Corporation|GRCE (Grace Therapeutics Inc) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio fireflyneuro.com (AIFF)|Market Cap to Net Assets Ratio Klotho Neurosciences Inc|Market Cap to Book Value Multiple neurosense-tx.com (NRSN)|Market Capitalization to Book Value Ratio RVPH|Market Capitalization to Book Value MetaVia Inc. MTVA|NRXS: Market Capitalization to Book Value Ratio|HSDT - Market Cap to Net Assets Ratio|PASG: Market Capitalization to Book Value Ratio|NEUP (Neuphoria Therapeutics) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp|Market Value to Book Value Ratio ATHA|ADXN (Addex Therapeutics) - Market Value to Book Value Ratio|Market Capitalization to Book Value alzamend.com (ALZN)|Market Capitalization to Book Value Ratio CYCN (Cyclerion Therapeutics, Inc.)|Protagenic Therapeutics Inc. - Market Capitalization to Book Value Ratio|KTTA: Market Value to Book Value Ratio|CRGT: Market Cap to Net Assets Ratio|Avenue Therapeutics (ATXI) - Market Value to Book Value Ratio|Market Value to Book Value Ratio brainstorm-cell.com|Market Cap to Net Assets Ratio Cara Therapeutics (CARA)|Capitalization to Book Value Ratio CHRO|Market Value to Book Value Ratio Eliem Therapeutics ELYM|Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|LBPH: Market Capitalization to Book Value Ratio|MRNS - Market-to-Book Ratio|NKGen Biotech - Market Cap to Net Assets Ratio|NRBO: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Sage Therapeutics, Inc SAGE|SNPX (Synaptogenix, Inc) - Market Value to Book Value|Market Value to Book Value Ratio TRVN (Trevena, Inc.)|Market-to-Book Ratio Vigil Neuro|Market Capitalization to Book Value Ratio WENA|Market Capitalization to Book Value Ratio CERE (Cerevel Therapeutics Inc)